-

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Announces Investigation into NovoCure Limited (NVCR)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether NovoCure Limited (“NovoCure” or the “Company”) (NYSE: NVCR) and certain of its officers and directors issued false and/or misleading statements and/or failed to disclose information pertinent to investors in violation of federal securities laws. If you purchased or otherwise own NovoCure securities, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312 for more information.

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

NovoCure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its Tumor Treating Fields ("TTFields") therapy.

On June 6, 2023, NovoCure issued a press release announcing "positive results" from the Phase 3 LUNAR clinical trial evaluating the use of its TTFields therapy together with standard therapies for the treatment of non-small cell lung cancer. Despite reporting an observable difference in median overall survival between patients receiving TTFields, combined with standard therapies compared patients treated only with standard therapies, analysts expressed concerns about the test population and the commercial prospects of the device.

On this news, NovoCure's stock fell from $82.51 per share to $47 per share, representing a decline of over 43%.

What You Can Do – CLICK HERE

If you purchased or otherwise own NovoCure securities and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312, or at jzimmerman@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Scott+Scott Attorneys at Law LLP

NYSE:NVCR

Release Versions

Contacts

More News From Scott+Scott Attorneys at Law LLP

UTZ BRANDS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Utz Brands, Inc.’s Directors and Officers for Breach of Fiduciary Duties – UTZ

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Utz Brands, Inc. (NYSE: UTZ) approved a buyout of Utz for inadequate consideration, breaching their fiduciary duties to Utz’s shareholders, and whether Utz’s shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On July 21, 2026, Utz announced it had reached an agreement...

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation’s Directors and Officers for Breach of Fiduciary Duties – CHE

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Chemed Corporation (NYSE: CHE) failed to manage Chemed in an acceptable manner, breaching their fiduciary duties to Chemed, and whether Chemed and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On August 13, 2026, The Capital Forum released a report alleging t...

L3HARRIS TECHNOLOGIES, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates L3Harris Technologies, Inc.’s Directors and Officers for Breach of Fiduciary Duties – LHX

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of L3Harris Technologies, Inc. (NYSE: LHX) failed to manage L3Harris in an acceptable manner, breaching their fiduciary duties to L3Harris, and whether L3Harris and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On August 17, 2026, L3Harris announced it had entered...
Back to Newsroom